Identity and synonyms
Catalog label is recorded; analytical identity and equivalence are not established.
Nonpeptide agent · Cofactor, nucleoside or nucleotide
Detailed molecular class: Nonpeptide agent; see mechanism for subtype
Supplied sequence or chemical reference
PubChem CID: 439153
Molecular formula: C21H29N7O14P2
IUPAC: [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
Source: PC-NAD-H
Database chemical reference; does not certify supplier vial, salt, isomer or formulation.
Mechanism
NADH is the reduced dinucleotide form; not NAD+ or a peptide.
Evidence and critical reading
Reported scientific and empirical uses
Mitochondrial research · Replacement and nutritional context
Oral supplementation and “energy” blends; do not assume equivalence to intravenous NAD+.
Human evidence
A 207-person ME/CFS trial studied NADH with CoQ10. The combination and within-group changes cannot attribute isolated NADH benefit or validate an injectable blend.
Preclinical evidence
Do not equate mechanism, cell culture or animal work with a clinical outcome. The specific level is detailed in the evidence assessment.
Critical reading and limitations
A 207-person ME/CFS trial studied NADH with CoQ10. The combination and within-group changes cannot attribute isolated NADH benefit or validate an injectable blend.
A 207-person ME/CFS trial studied NADH with CoQ10. The combination and within-group changes cannot attribute isolated NADH benefit or validate an injectable blend.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by Effect of Dietary Coenzyme Q10 Plus NADH Supplementation on Fatigue Perception and Health-Related Quality of Life in Individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial.
20 mg · Daily amount of a combination component
- Frequency
- Daily
- Duration
- 12 weeks
- Route
- Oral
- Context
- NADH with CoQ10 200 mg/day in ME/CFS; not isolated NADH effect.
- Presentation
- A dosage-form presentation is not specified in the reviewed record.
- Interpretation
- Research exposure: not a prescription or starting regimen. It does not reconstruct protocol titration, exclusions or monitoring.
PMID34444817 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Empirical handbook
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Regulation and safety
Jurisdiction-specific regulatory context
This record does not verify FDA/EMA authorization of the commercial identity. Where a specific medicine/product exists, jurisdiction/indication are detailed in cited sources; they do not transfer to supplier material.
Adverse effects and unknowns
Reduced form, stability and combination matter; do not extrapolate capsule safety to a multicomponent vial.
Contraindications
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
NADH · 267 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT07808333 · Nicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial)Registry status: Not yet recruitingLast update posted: October 13, 2026Query verification: October 16, 2026
NCT06726369 · A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid TumorsRegistry status: RecruitingLast update posted: October 13, 2026Query verification: October 16, 2026
NCT07144527 · Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older AdultsRegistry status: RecruitingLast update posted: October 7, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PC-NAD-H
October 16, 2026
- PMID34444817
Castro-Marrero J, Segundo MJ, Lacasa M, Martinez-Martinez A, Sentañes RS, Alegre-Martin J.
October 16, 2026
- SEARCH-PUBMED-nad-h
PubMed/MED targeted search: TITLE_ABS:NADH AND TITLE_ABS:"chronic fatigue" AND TITLE_ABS:trial
October 16, 2026